Growth hormone treatment of children with short stature secondary to intra-uterine growth retardation: effect of 2 years' treatment and 2 years' follow-up.
Growth hormone (GH) treatment has been proposed to improve final height in patients with short stature associated with intra-uterine growth retardation (IUGR). In this study, 30 prepubertal patients aged 9.5 +/- 0.9 years with IUGR and normal GH secretion on pharmacological testing were treated with GH. These patients had a mean birth length of -3.11 +/- 0.80 SDS, and mean growth retardation of -2.58 +/- 0.49 SDS for chronological age. GH, 1.4 IU/kg/week (= 0.07 mg/kg/day), was given for 2 years. Height gain (calculated as the difference of height SDS at baseline and after 2 years) was 1.3 +/- 0.4 SD and was not significantly correlated with height SDS or growth velocity at baseline. These data confirm that 2 years of recombinant human GH treatment increases height gain in patients with IUGR. Two years after treatment interruption, mean gain was maintained at +1.08 SDS and 83% of the children had normal height.